Wet age-related macular degeneration (wet AMD) is an eye condition that can impact how clearly you see. This can make everyday life difficult and challenging. Learning about what’s happening in your eye can help you better understand how treatment works.
How wet AMD affects the eye
A protein called VEGF is known to be a primary driver of the disease causing the underlying issues in the eye:
Blood vessels grow abnormally in the eye
The blood vessels leak fluid into a part of the eye called the macula
The macula swells, leading to blurred vision and vision loss
How wet AMD affects your vision
Slide to see how wet AMD may impact your vision:
Blurry or blind spots can appear in the center of your vision
Slide to see how wet AMD may impact your vision:
Straight lines appear wavy
Slide to see how wet AMD may impact your vision:
Colors appear less vibrant
Slide to see how wet AMD may impact your vision:
Trouble seeing in low lighting
Slide to see how wet AMD may impact your vision:
Blurry or blind spots can appear in the center of your vision
Slide to see how wet AMD may impact your vision:
Straight lines appear wavy
Slide to see how wet AMD may impact your vision:
Colors appear less vibrant
Slide to see how wet AMD may impact your vision:
Trouble seeing in low lighting
How wet AMD affects your life
Traditional treatments for wet AMD involve anti-VEGF injections into the eye, which are designed to block VEGF proteins, improving and maintaining vision. However, these injections usually need to be given on a regular basis. Frequent visits to your retina specialist may take away from your free time and eye injections can be a daunting experience for some people with wet AMD.
If you’re looking for a different treatment option, talk with a Retina Specialist and find out if SUSVIMO® is right for you
-
-
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
-
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
-
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
-
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
-
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
-
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
-
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
-
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
-
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
-
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
-
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
-
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
-
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
-
-